Topic: natural killer cells
A2 Biotherapeutics is launching with $57 to pursue cell therapies for solid tumors, an area in which CAR-T treatments have run into difficulties.
The deal grants Takeda rights to up to four programs, including natural killer cell therapies aimed at CD19 and BCMA.
The commercial potential of CAR-Ts is constrained by a range of logistical and safety issues. Nkarta thinks engineered natural killer cells can eliminate those constraints, resulting in better therapies equipped to go mainstream.
Nkarta now has the runway to start clinical trials for its natural killer cell therapy, build a manufacturing site and advance its early-stage pipeline.
A protein originally developed to boost the power of T cells in treating cancer protected normal mice from developing cancer in the first place.
Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million for access to four more natural killer (NK) cell-based programs.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
M.D. Anderson Cancer Center researchers are developing a CAR-T alternative derived from umbilical cord blood.
Celgene has landed an option on four natural killer cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics.
Sorrento Therapeutics is creating a joint venture with South Korea’s CHA Biotech to develop chimeric antigen receptor modified cellular therapies based on activated killer cell technology.